Geron is developing first-in-class biopharmaceuticals for the
treatment of cancer and chronic degenerative diseases, including spinal
cord injury, heart failure and diabetes. The company is advancing an anti-
cancer drug and a cancer vaccine that target the enzyme telomerase through
multiple clinical trials in different cancers.